Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 2991-2997

  Sarbia, Mario ^a   Stahl, Michael ^b   Fink, Ulrich ^c   Willers, Rainhart ^a   Seeber, Siegfried ^b   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGUS CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032407541     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Müller, J. M., Erasmi, H., Stelzner, M., Zieren, U., and Pichlmaier, H. Surgical therapy of oesophageal carcinoma. Br. J. Surg., 77: 845-857, 1990.
2. Ilson, D. H., and Kelsen, D. P. Combined modality therapy in the treatment of esophageal cancer. Semin. Oncol., 21: 493-507, 1994.
3. Forastiere, A. A., Heitmiller, R. F., and Kleinberg, L. Multimodality therapy for esophageal cancer. Chest, 112: 195S-200S, 1997.
4. Bosset, J. F., Gignoux, M., Triboulet, J. P., Tiret, E., Mantion, G., Elias, D., Lozach, P., Ollier, J. C., Pavy, J. J., Mercier M., and Sahmoud, S. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med., 337: 161-167, 1997.
5. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
6. Meyn, R. E., Stephens, L. C., and Milas, L. Programmed cell death and radioresistance. Cancer Metastasis Rev., 75: 119-131, 1996.
7. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
8. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7: 547-553, 1995.
9. Strasser, A., Huang, D. C. S., and Vaux, D. L. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochem. Biophys. Acta, 1333: F151-F178, 1997.
10. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
11. Sedlak, T. W., Oltvai, Z. N., Yang, E., Wang, K., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. USA, 92: 7834-7838, 1995.
12. Righetti, S. C., Delia Torre, G., Pilotti, S., Menard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Böhm, S., Bresciani, G. L., Spatti, G., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
13. McDonnel, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
14. Krajewski, S., Blomqvist, C., Fransila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
15. Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C., and Lichtenstein A. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res., 58: 256-262, 1998.
16. Stahl, M., Wilke, H., Fink, U., Stuschke, M., Walz, M. K., Siewert, J. R., Molls, M., Fett, W., Makoski, H. B., Breuer, N., Schmidt, U., Niebel, W., Sack, H., Eigler, F. W., and Seeber, S. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: interim analysis of a phase II trial. J. Clin. Oncol., 14: 829-837, 1996.
17. International Union Against Cancer. TNM Classification of Malignant Tumours, Ed. 4., 2nd Rev. Berlin: Springer, 1992.
18. WHO. Histological Typing of Oesophageal and Gastric Tumours, Ed. 2. Berlin: Springer, 1990.
19. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
20. Kaplan, E. L., and Meier, P. Nonparametric estimation for incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
21. Bennett, W. P., Hollstein, M. C., He, A., Zhu, S. M., Resau, J. H., Trump, B. F., Metcalf, R. A., Welsh, J. A., Cannon, J. V., Lane, D. P., and Harris, C. C. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene, 6: 1779-1784, 1991.
22. Wagata, T., Shibagaki, I., Imamura, M., Shimada, Y., Toguchida, J., Yandell, D. W., Ikenaga, M., Tobe, T., and Ishizaki, K. Loss of 17p, mutation of the p53 gene, and overexpression of the p53 protein in esophageal squamous cell carcinomas. Cancer Res., 53: 846-850, 1993.